After removing semaglutide (Ozempic, Wegovy) from the drug shortage list in early 2025, the FDA stated that 503A and 503B facilities may no longer compound copies of semaglutide for general distribution
Diabetes Care 36:29452951 Fonseca VA, Alvarado-Ruiz R, Raccah D et al (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
GHK-Cu's anti-inflammatory properties may provide some benefit in autoimmune hair loss, reducing the inflammatory assault on follicles
However, owing to the inhibition of ACC, this effect does not promote liver steatosis and can reduce blood glucose levels
The growing popularity of GLP-1 receptor agonistsincluding Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lillyhas added fuel to an already fiery debate over the governments role in subsidizing access to these drugs
People experience diarrhea and drink more water